November 28, 2025 • 13 mins
Methylene blue’s mitochondrial effects, oxidative stress repair, dosing risks, MAO inhibition, serotonin syndrome, sourcing, and the economics blocking large trials.
In this episode, we trace the surprising evolution of methylene blue from a lab dye to a potential mitochondrial enhancer. We explain how it participates in electron shuttling, improves electron transport chain efficiency, and reduces oxidative stress—mechanisms that may underlie early findings in both brain and metabolic health. We also explore its effects on mitochondrial biogenesis, illuminating why interest in this compound has surged.
But the promise comes with sharp edges. We break down the narrow dosing window, the possibility of reductive stress, and the serious risks tied to MAO inhibition, especially when combined with SSRIs or SNRIs. You’ll learn how serotonin syndrome can be misdiagnosed, the clinical red flags to watch for, and why medical supervision is non-negotiable.
We place these conversations in context by examining methylene blue’s established hospital use for methemoglobinemia, and then explore the economic barriers: how off-patent drugs often lack the financial incentive needed for large-scale trials.
The episode ends with a framework for weighing personal risk versus mechanistic promise, offering practical safeguards for anyone considering this compound.
Health professional oversight is strongly recommended due to risk of unknown dosing standards and lack of sufficient clinical trials.
Listener Takeaways:
• How methylene blue supports mitochondria and reduces oxidative stress
• Its electron shuttling and biogenesis effects
• The dangers: MAO inhibition, SSRIs, serotonin syndrome
• Sourcing standards, red flags, and medical oversight
• Why economics block large trials on off-patent drugs
Follow for daily longevity and wellness episodes.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_01 (00:00):
Welcome to the Deep Dive.
(00:01):
Today we are taking a long,serious look at a substance that
has, well, one of the mostunexpected trajectories in
modern health, methylene blue,or MB.
For years, most people only knewit as a dye, maybe something
used to stain cells in a biologylab, or maybe even an antifungal
for cleaning fish tanks.
SPEAKER_00 (00:18):
And of course, in the last few years, its profile
just exploded.
It was seen being used bycertain public figures on social
media, treating it almost likea, you know, anotropic
supplement.
This viral visibility has reallypropelled MB from the aquarium
aisle into, well, seriousconversations about human
health.
SPEAKER_01 (00:36):
Aaron Powell Exactly.
It's an old compound, it'sremarkably cheap, and now it has
fully entered the supplementdiscussion for internal
consumption.
So our mission today is prettycritical.
We need to unpack the sourcesand figure out what the science
actually says.
Is methylene blue this powerful,beneficial intervention for our
body's fundamental processes?
Or are the risks and theregulatory unknowns simply too
(00:56):
high to ignore?
SPEAKER_00 (00:57):
What stands out immediately is that while MB has
been used clinically for variousniche things for decades, its
function is almost monolithic.
Every single effect it has onhuman biology, good or bad, it
traces right back to its directinteraction with the
mitochondria.
It is primarily, and maybe evenexclusively, a mitochondrial
agent.
SPEAKER_01 (01:17):
Aaron Powell Okay, let's start there then, right at
the heart of the cell.
When we talk about mitochondriaproducing energy, we're talking
about the electron transportchain, the ETC.
For listeners familiar with thebasics, we know ATP is generated
by electrons flowing throughthese complexes.
But where exactly does methyleneblue, you know, plug into that?
SPEAKER_00 (01:35):
Aaron Powell That's where the power lies.
The ETC is basically a highlyefficient biological battery
charging system.
When it's working right,electrons flow smoothly, energy
is produced.
But when the system getssluggish, you know, due to
aging, stress, toxins, electronscan leak out.
SPEAKER_01 (01:51):
And when those electrons leak, that's when the
trouble starts, isn't it?
SPEAKER_00 (01:54):
That's exactly right.
They are highly reactive, theyjump off the chain, and they
combine with oxygen, creatingwhat we call reactive oxygen
species, or ROS.
This whole cascade of damage iswhat we call oxidative stress,
and it is corrosive to the cell.
SPEAKER_01 (02:07):
We hear that term oxidative stress all the time,
but let's just underline itsimportance.
What does decades of evidencetell us about what happens when
ROS gets out of control?
SPEAKER_00 (02:16):
Well, we have overwhelming evidence linking
elevated oxidative stress andmitochondrial dysfunction to the
very root of major chronichealth issues.
And this isn't just aboutgeneral aging.
We're talking aboutneurodegeneration conditions
like Alzheimer's andParkinson's, also metabolic
disorders like obesity and type2 diabetes.
And on top of that, it'simplicated in a surprisingly
(02:38):
wide array of neuropsychiatricdisorders.
So if we can stabilize the ETC,we are targeting something
really fundamental.
SPEAKER_01 (02:44):
Okay, so if the ETC is leaking electrons, methylene
blue acts as the uh ultimatestopgap.
Tell us more about its specificrole as this electron shuttle.
SPEAKER_00 (02:53):
So methylene blue has this unique property.
It can exist in an oxidizedstate and a reduced state.
It acts as a bypass.
It's capable of acceptingelectrons from complex EO of the
ETC, where a lot of these leaksstart, and then immediately
donating them back further downthe chain, typically at complex
four.
This action bypasses the damagedsection, keeps the electron flow
(03:14):
going, and most importantly, itprevents those electrons from
reacting with oxygen to formROS.
By catching and redirectingthose electrons, ME effectively,
well, it calms down the cellularchaos caused by oxidative
stress.
SPEAKER_01 (03:27):
That framing really helps.
So it's essentially an auxiliarypath like restoring efficiency
to a damaged power grid.
SPEAKER_00 (03:32):
Exactly.
And because this mechanism is sofoundational, I mean literally
improving the core energyproduction of the cell, that's
why the theoretical benefits areso broad.
SPEAKER_01 (03:41):
But this is where the conversation takes a turn
toward complexity, becausestabilizing a biological system
often relies on, you know, aperfect equilibrium.
You suggested that methyleneblue presents a serious dosage
paradox.
If we use it to fight oxidativestress, what happens if we use
too much?
SPEAKER_00 (03:57):
This is the tightrope walk.
Oxidative stress is too muchoxidation.
The cell is, in essence,resting.
But the opposite state,reductive stress, is equally
problematic.
This happens if you acceptelectrons too aggressively, if
you just overload the systemwith reducing agents.
The ETC gets so saturated thatthe whole process stalls, and
(04:18):
this electron bottleneck ishighly damaging in its own
right.
SPEAKER_01 (04:22):
So methylene blue, the very thing celebrated for
reducing stress, can actuallybecome a source of stress if the
dose is too high.
SPEAKER_00 (04:28):
Precisely.
If MB is given in doses that aretoo aggressive for the cell's
current metabolic state, itbecomes a reductive stressor.
And reductive stress isn't justsome theoretical problem, we see
clinical connections here too.
Studies have found reductivestress in the brains of people
with certain severe conditions,including schizophrenia and
bipolar disorder.
SPEAKER_01 (04:46):
That raises a huge question then.
If the goal is balance, howconfident can we be in
self-regulating this highlypotent biological switch?
SPEAKER_00 (04:55):
It's tremendously difficult.
Unlike, say, vitamins, where thedifference between a helpful
dose and a harmful dose is oftenmassive.
With a potent mitochondrialagent like MB, that therapeutic
window is small.
Very small.
The difference between optimalelectron shuttling and inducing
reductive stress might be verysubtle, and it depends on
(05:15):
individual metabolic demands.
SPEAKER_01 (05:17):
But despite that complexity, are the early
findings promising enough towarrant more investigation?
What are the pilot studiessuggesting?
SPEAKER_00 (05:25):
The initial data is compelling, mainly because of
its breadth.
We are seeing small, non-idealpilot trials, and remember,
these are not large phase threetrials, that suggest potential
benefits across a really widerange of neuropsychiatric
disorders.
This includes classicdepression, bipolar disorder,
schizophrenia, and evenneurodegenerative conditions
like Alzheimer's disease.
SPEAKER_01 (05:46):
And the mechanism isn't just limited to shuttling
electrons, is it?
SPEAKER_00 (05:49):
No, it's not.
Beyond the electron transfer,methylene blue is also suggested
to promote mitochondrialbiogenesis, which just means the
creation of new healthymitochondria.
And naturally, by calming downthat internal inflammation from
ROS, it also shows significantanti-inflammatory effects.
So we have multiple beneficialavenues all converging.
SPEAKER_01 (06:09):
Aaron Powell Okay.
So we have strong underlyingmechanisms in inexpensive
compound and preliminary humandata suggesting broad
therapeutic use, especially inneurological health.
But this brings us to thesegment that demands the most
caution and the closestattention from you, the
listener.
This is the major potentiallyfatal pharmacological risk.
SPEAKER_00 (06:27):
Aaron Powell We have to talk about the elephant in
the room.
Methylene blews monoamineoxidase activity, or MAO
activity.
This is the crucial risk factorthat separates MB from almost
every other common supplementout there.
SPEAKER_01 (06:39):
For those unfamiliar with that enzyme system, why
does MAO activity introduce sucha profound danger when we talk
about supplementing?
SPEAKER_00 (06:46):
Monoamine oxidase is an enzyme, and its job is to
break down keyneurotransmitters.
This includes dopamine, norpinephrine, and critically, in
this context, serotonin.
When methylene blue isintroduced, it acts as an MAO
inhibitor.
It stops that enzyme fromworking effectively.
So if you stop the enzyme frombreaking down serotonin, the
amount of serotonin in yourbrain and your body can just
(07:08):
skyrocket.
And this is especially dangerousif you're already on common
prescribed medications.
SPEAKER_01 (07:14):
Right.
So if someone is taking an SSRI,a selective serotonin reuptake
inhibitor, they are alreadypreventing the reabsorption of
serotonin, keeping more of itactive.
Then you introduce methyleneblue, an MAO inhibitor, and you
are essentially stopping itsbreakdown entirely.
SPEAKER_00 (07:29):
That is the perfect storm.
You are hitting the serotoninsystem from two different
pharmacological directions.
You're stopping the cleanup andyou're blocking the
reabsorption.
This makes the risk of serotoninsyndrome profound.
SPEAKER_01 (07:40):
I want to spend a moment on the specific
behavioral science aroundserotonin and reward, because I
found the source material onthis just fascinating.
We tend to associate rewardingexperiences with a huge spike in
dopamine.
But the Stanford LabMousestudies, they showed a more
nuanced relationship.
SPEAKER_00 (07:57):
They did.
This work highlighted that foran experience to be truly
reinforcing, for the brain tosay, I want to do that again, it
relied not just on the increasein dopamine, but on a concurrent
drop in serotonin levels.
It seems the rewarding signalrequires this delicate ratio
between those two systems.
SPEAKER_01 (08:15):
So if MB is raising serotonin levels
pharmacologically, it could beunintentionally disrupting this
natural balance, potentiallyoffsetting the rewarding or
motivating aspects of otherwisehealthy behaviors.
SPEAKER_00 (08:27):
Precisely.
You're tampering with thefundamental reinforcement
mechanism of the brain.
But honestly, that behavioralrisk, it pales in comparison to
the acute toxicity risk.
The true danger of combining MBwith high serotonin medications
is serotonin syndrome.
SPEAKER_01 (08:41):
Describe what this looks like because this is the
information that could literallysave a life if someone is out
there experimenting with MB.
SPEAKER_00 (08:47):
Serotonin syndrome is a toxic excess of serotonin
in the central nervous system.
The symptoms are often initiallymistaken for simple anxiety or a
panic attack.
Things like intense jitteriness,restlessness, confusion, rapid
heart rate, severe nausea ordiarrhea.
In its most severe presentation,it can lead to high fevers,
muscle rigidity, seizures, andultimately death.
(09:10):
This is not a slight sideeffect, it's a life-threatening
medical emergency.
SPEAKER_01 (09:15):
And what makes this so heartbreaking in the sources
we looked at is that it is oftencompletely misdiagnosed in a
clinical setting.
SPEAKER_00 (09:20):
That's the tragedy.
If a patient comes in who'salready being treated for, say,
depression or bipolar disorder,and they report severe anxiety,
restlessness, jitters, theimmediate clinical bias is to
assume their underlyingpsychiatric condition is getting
worse.
They're already defined as apsychiatric patient.
SPEAKER_01 (09:36):
So instead of recognizing a toxic
pharmacological reaction, thepractitioner might just
interpret the symptoms asincreased anxiety.
SPEAKER_00 (09:44):
And then the worst possible outcome follows.
The doctor, trying to treat theworsening anxiety, increases the
dose of the SSRI or adds anotherserotonergic medication.
This is just pouring tool on thefire.
It exacerbates the serotoninsyndrome and often leads to
devastating outcomes.
It's a spiral of misdiagnosis.
SPEAKER_01 (10:02):
That anecdote from the sources about the woman who
finally figured this outherself, it really drives home
how insidious this can be.
SPEAKER_00 (10:09):
It does.
She was taking her prescribedmedications for a long time,
suffering from these chronic,strange symptoms, constant
anxiety, physical jitters thatwere consistently written off as
just her existing condition.
It was only after she began herown research and critically
started to slowly taper off hermedications with your
psychiatrist's guidance thatboth she and her doctor realized
(10:31):
those symptoms had been textbookserotonin syndrome all along,
caused by the therapeutic dosesshe was taking.
An agent like methylene blue,added casually, could push
someone into that catastrophicstate instantly.
This just underscores theabsolute necessity of consulting
a physician before evercombining MB with any
psychoactive medication.
SPEAKER_01 (10:49):
That perspective is crucial.
So let's move to thepracticalities.
If someone is determined toexplore MB use, what are the
basic ground rules on sourcingand consumption?
SPEAKER_00 (10:59):
First and foremost, you have to verify the source.
Purity is everything, especiallywith a compound that requires
such precise dosing.
Do not use industrial oraquarium grade chemicals.
You have to seek outpharmaceutical grade suppliers.
Secondly, be prepared for thecosmetic consequences.
MB is a dye and a potent one.
It will turn your tongue, yourteeth, and your urine a bright
(11:21):
blue.
It's a very obvious indicatorthat you've consumed it.
SPEAKER_01 (11:24):
And while consumer interest is booming, we should
know that MB isn't completelyforeign to institutional
medicine.
It is used in certain hospitalsettings, right?
SPEAKER_00 (11:32):
Absolutely.
4V infusions of pharmaceuticalgrade methylene blue are a
medically approved treatment forspecific conditions, like
methmoglobinemia, which is ablood disorder.
The key takeaway there is thatit can be administered safely
and effectively, but only understrict medical supervision where
dosage and interactions can bemeticulously controlled.
SPEAKER_01 (11:52):
So we have a powerful mechanism, historical
use, compelling preliminarydata.
Why then are we not seeing thedefinitive large-scale phase
three clinical trials, therandomized controlled trials
that would solidify MB's placein modern medicine?
SPEAKER_00 (12:07):
The answer, unfortunately, is purely
economic.
Methylene blue has been aroundfor over a century.
It's off-patent.
There is zero intellectualproperty protection.
SPEAKER_01 (12:16):
Aaron Powell Meaning there's no profit incentive.
SPEAKER_00 (12:18):
Precisely.
To develop a drug for alarge-scale indication like
Alzheimer's or schizophrenia, itrequires investing hundreds of
millions, sometimes billions ofdollars, into large-scale safety
and efficacy trials.
No pharmaceutical company isgoing to make that investment if
the resulting drug can't bepatented and protected for
profit.
And this leaves a massive andfrustrating gap.
(12:38):
The compound is promising, theneed is great, but the financial
structure of medical innovationjust leaves it in research
limbo, limited to smalleracademic or government-funded
pilot studies.
SPEAKER_01 (12:48):
So, what does this all mean when we bring these
points together?
We have identified methyleneblue as an incredibly potent,
inexpensive mitochondrial agent.
It has undeniable potential toaddress deep physiological
issues like oxidative stress andmitochondrial decay factors
driving aging and a host ofdisorders.
Yet it sits on the sharp edge ofa razor blade.
(13:10):
It carries a serious,potentially fatal
pharmacological risk serotoninsyndrome.
If the dosage is misjudged or ifit interacts with common
medications, it's a genuinehigh-stakes dichotomy.
SPEAKER_00 (13:21):
It is a perfect encapsulation of the current
landscape of healthinterventions.
And that leaves us with aprovocative question for you to
consider.
Given this powerful mechanismand the consistent, promising
preliminary data, data thatcan't progress because of its
off patent economic status, howshould you, as an individual
seeking to optimize your health,weigh that potential reward
against the serious, welldocumented pharmacological risks
(13:43):
before pursuing such a novelintervention?
The balance between curiosityand caution has never been more
critical.
SPEAKER_01 (13:49):
A compelling and essential thought to Mullover.
Thank you for joining us on thisdeep dive.
Welcome to the Deep Dive.
(00:01):
Today we are taking a long,serious look at a substance that
has, well, one of the mostunexpected trajectories in
modern health, methylene blue,or MB.
For years, most people only knewit as a dye, maybe something
used to stain cells in a biologylab, or maybe even an antifungal
for cleaning fish tanks.
SPEAKER_00 (00:18):
And of course, in the last few years, its profile
just exploded.
It was seen being used bycertain public figures on social
media, treating it almost likea, you know, anotropic
supplement.
This viral visibility has reallypropelled MB from the aquarium
aisle into, well, seriousconversations about human
health.
SPEAKER_01 (00:36):
Aaron Powell Exactly.
It's an old compound, it'sremarkably cheap, and now it has
fully entered the supplementdiscussion for internal
consumption.
So our mission today is prettycritical.
We need to unpack the sourcesand figure out what the science
actually says.
Is methylene blue this powerful,beneficial intervention for our
body's fundamental processes?
Or are the risks and theregulatory unknowns simply too
(00:56):
high to ignore?
SPEAKER_00 (00:57):
What stands out immediately is that while MB has
been used clinically for variousniche things for decades, its
function is almost monolithic.
Every single effect it has onhuman biology, good or bad, it
traces right back to its directinteraction with the
mitochondria.
It is primarily, and maybe evenexclusively, a mitochondrial
agent.
SPEAKER_01 (01:17):
Aaron Powell Okay, let's start there then, right at
the heart of the cell.
When we talk about mitochondriaproducing energy, we're talking
about the electron transportchain, the ETC.
For listeners familiar with thebasics, we know ATP is generated
by electrons flowing throughthese complexes.
But where exactly does methyleneblue, you know, plug into that?
SPEAKER_00 (01:35):
Aaron Powell That's where the power lies.
The ETC is basically a highlyefficient biological battery
charging system.
When it's working right,electrons flow smoothly, energy
is produced.
But when the system getssluggish, you know, due to
aging, stress, toxins, electronscan leak out.
SPEAKER_01 (01:51):
And when those electrons leak, that's when the
trouble starts, isn't it?
SPEAKER_00 (01:54):
That's exactly right.
They are highly reactive, theyjump off the chain, and they
combine with oxygen, creatingwhat we call reactive oxygen
species, or ROS.
This whole cascade of damage iswhat we call oxidative stress,
and it is corrosive to the cell.
SPEAKER_01 (02:07):
We hear that term oxidative stress all the time,
but let's just underline itsimportance.
What does decades of evidencetell us about what happens when
ROS gets out of control?
SPEAKER_00 (02:16):
Well, we have overwhelming evidence linking
elevated oxidative stress andmitochondrial dysfunction to the
very root of major chronichealth issues.
And this isn't just aboutgeneral aging.
We're talking aboutneurodegeneration conditions
like Alzheimer's andParkinson's, also metabolic
disorders like obesity and type2 diabetes.
And on top of that, it'simplicated in a surprisingly
(02:38):
wide array of neuropsychiatricdisorders.
So if we can stabilize the ETC,we are targeting something
really fundamental.
SPEAKER_01 (02:44):
Okay, so if the ETC is leaking electrons, methylene
blue acts as the uh ultimatestopgap.
Tell us more about its specificrole as this electron shuttle.
SPEAKER_00 (02:53):
So methylene blue has this unique property.
It can exist in an oxidizedstate and a reduced state.
It acts as a bypass.
It's capable of acceptingelectrons from complex EO of the
ETC, where a lot of these leaksstart, and then immediately
donating them back further downthe chain, typically at complex
four.
This action bypasses the damagedsection, keeps the electron flow
(03:14):
going, and most importantly, itprevents those electrons from
reacting with oxygen to formROS.
By catching and redirectingthose electrons, ME effectively,
well, it calms down the cellularchaos caused by oxidative
stress.
SPEAKER_01 (03:27):
That framing really helps.
So it's essentially an auxiliarypath like restoring efficiency
to a damaged power grid.
SPEAKER_00 (03:32):
Exactly.
And because this mechanism is sofoundational, I mean literally
improving the core energyproduction of the cell, that's
why the theoretical benefits areso broad.
SPEAKER_01 (03:41):
But this is where the conversation takes a turn
toward complexity, becausestabilizing a biological system
often relies on, you know, aperfect equilibrium.
You suggested that methyleneblue presents a serious dosage
paradox.
If we use it to fight oxidativestress, what happens if we use
too much?
SPEAKER_00 (03:57):
This is the tightrope walk.
Oxidative stress is too muchoxidation.
The cell is, in essence,resting.
But the opposite state,reductive stress, is equally
problematic.
This happens if you acceptelectrons too aggressively, if
you just overload the systemwith reducing agents.
The ETC gets so saturated thatthe whole process stalls, and
(04:18):
this electron bottleneck ishighly damaging in its own
right.
SPEAKER_01 (04:22):
So methylene blue, the very thing celebrated for
reducing stress, can actuallybecome a source of stress if the
dose is too high.
SPEAKER_00 (04:28):
Precisely.
If MB is given in doses that aretoo aggressive for the cell's
current metabolic state, itbecomes a reductive stressor.
And reductive stress isn't justsome theoretical problem, we see
clinical connections here too.
Studies have found reductivestress in the brains of people
with certain severe conditions,including schizophrenia and
bipolar disorder.
SPEAKER_01 (04:46):
That raises a huge question then.
If the goal is balance, howconfident can we be in
self-regulating this highlypotent biological switch?
SPEAKER_00 (04:55):
It's tremendously difficult.
Unlike, say, vitamins, where thedifference between a helpful
dose and a harmful dose is oftenmassive.
With a potent mitochondrialagent like MB, that therapeutic
window is small.
Very small.
The difference between optimalelectron shuttling and inducing
reductive stress might be verysubtle, and it depends on
(05:15):
individual metabolic demands.
SPEAKER_01 (05:17):
But despite that complexity, are the early
findings promising enough towarrant more investigation?
What are the pilot studiessuggesting?
SPEAKER_00 (05:25):
The initial data is compelling, mainly because of
its breadth.
We are seeing small, non-idealpilot trials, and remember,
these are not large phase threetrials, that suggest potential
benefits across a really widerange of neuropsychiatric
disorders.
This includes classicdepression, bipolar disorder,
schizophrenia, and evenneurodegenerative conditions
like Alzheimer's disease.
SPEAKER_01 (05:46):
And the mechanism isn't just limited to shuttling
electrons, is it?
SPEAKER_00 (05:49):
No, it's not.
Beyond the electron transfer,methylene blue is also suggested
to promote mitochondrialbiogenesis, which just means the
creation of new healthymitochondria.
And naturally, by calming downthat internal inflammation from
ROS, it also shows significantanti-inflammatory effects.
So we have multiple beneficialavenues all converging.
SPEAKER_01 (06:09):
Aaron Powell Okay.
So we have strong underlyingmechanisms in inexpensive
compound and preliminary humandata suggesting broad
therapeutic use, especially inneurological health.
But this brings us to thesegment that demands the most
caution and the closestattention from you, the
listener.
This is the major potentiallyfatal pharmacological risk.
SPEAKER_00 (06:27):
Aaron Powell We have to talk about the elephant in
the room.
Methylene blews monoamineoxidase activity, or MAO
activity.
This is the crucial risk factorthat separates MB from almost
every other common supplementout there.
SPEAKER_01 (06:39):
For those unfamiliar with that enzyme system, why
does MAO activity introduce sucha profound danger when we talk
about supplementing?
SPEAKER_00 (06:46):
Monoamine oxidase is an enzyme, and its job is to
break down keyneurotransmitters.
This includes dopamine, norpinephrine, and critically, in
this context, serotonin.
When methylene blue isintroduced, it acts as an MAO
inhibitor.
It stops that enzyme fromworking effectively.
So if you stop the enzyme frombreaking down serotonin, the
amount of serotonin in yourbrain and your body can just
(07:08):
skyrocket.
And this is especially dangerousif you're already on common
prescribed medications.
SPEAKER_01 (07:14):
Right.
So if someone is taking an SSRI,a selective serotonin reuptake
inhibitor, they are alreadypreventing the reabsorption of
serotonin, keeping more of itactive.
Then you introduce methyleneblue, an MAO inhibitor, and you
are essentially stopping itsbreakdown entirely.
SPEAKER_00 (07:29):
That is the perfect storm.
You are hitting the serotoninsystem from two different
pharmacological directions.
You're stopping the cleanup andyou're blocking the
reabsorption.
This makes the risk of serotoninsyndrome profound.
SPEAKER_01 (07:40):
I want to spend a moment on the specific
behavioral science aroundserotonin and reward, because I
found the source material onthis just fascinating.
We tend to associate rewardingexperiences with a huge spike in
dopamine.
But the Stanford LabMousestudies, they showed a more
nuanced relationship.
SPEAKER_00 (07:57):
They did.
This work highlighted that foran experience to be truly
reinforcing, for the brain tosay, I want to do that again, it
relied not just on the increasein dopamine, but on a concurrent
drop in serotonin levels.
It seems the rewarding signalrequires this delicate ratio
between those two systems.
SPEAKER_01 (08:15):
So if MB is raising serotonin levels
pharmacologically, it could beunintentionally disrupting this
natural balance, potentiallyoffsetting the rewarding or
motivating aspects of otherwisehealthy behaviors.
SPEAKER_00 (08:27):
Precisely.
You're tampering with thefundamental reinforcement
mechanism of the brain.
But honestly, that behavioralrisk, it pales in comparison to
the acute toxicity risk.
The true danger of combining MBwith high serotonin medications
is serotonin syndrome.
SPEAKER_01 (08:41):
Describe what this looks like because this is the
information that could literallysave a life if someone is out
there experimenting with MB.
SPEAKER_00 (08:47):
Serotonin syndrome is a toxic excess of serotonin
in the central nervous system.
The symptoms are often initiallymistaken for simple anxiety or a
panic attack.
Things like intense jitteriness,restlessness, confusion, rapid
heart rate, severe nausea ordiarrhea.
In its most severe presentation,it can lead to high fevers,
muscle rigidity, seizures, andultimately death.
(09:10):
This is not a slight sideeffect, it's a life-threatening
medical emergency.
SPEAKER_01 (09:15):
And what makes this so heartbreaking in the sources
we looked at is that it is oftencompletely misdiagnosed in a
clinical setting.
SPEAKER_00 (09:20):
That's the tragedy.
If a patient comes in who'salready being treated for, say,
depression or bipolar disorder,and they report severe anxiety,
restlessness, jitters, theimmediate clinical bias is to
assume their underlyingpsychiatric condition is getting
worse.
They're already defined as apsychiatric patient.
SPEAKER_01 (09:36):
So instead of recognizing a toxic
pharmacological reaction, thepractitioner might just
interpret the symptoms asincreased anxiety.
SPEAKER_00 (09:44):
And then the worst possible outcome follows.
The doctor, trying to treat theworsening anxiety, increases the
dose of the SSRI or adds anotherserotonergic medication.
This is just pouring tool on thefire.
It exacerbates the serotoninsyndrome and often leads to
devastating outcomes.
It's a spiral of misdiagnosis.
SPEAKER_01 (10:02):
That anecdote from the sources about the woman who
finally figured this outherself, it really drives home
how insidious this can be.
SPEAKER_00 (10:09):
It does.
She was taking her prescribedmedications for a long time,
suffering from these chronic,strange symptoms, constant
anxiety, physical jitters thatwere consistently written off as
just her existing condition.
It was only after she began herown research and critically
started to slowly taper off hermedications with your
psychiatrist's guidance thatboth she and her doctor realized
(10:31):
those symptoms had been textbookserotonin syndrome all along,
caused by the therapeutic dosesshe was taking.
An agent like methylene blue,added casually, could push
someone into that catastrophicstate instantly.
This just underscores theabsolute necessity of consulting
a physician before evercombining MB with any
psychoactive medication.
SPEAKER_01 (10:49):
That perspective is crucial.
So let's move to thepracticalities.
If someone is determined toexplore MB use, what are the
basic ground rules on sourcingand consumption?
SPEAKER_00 (10:59):
First and foremost, you have to verify the source.
Purity is everything, especiallywith a compound that requires
such precise dosing.
Do not use industrial oraquarium grade chemicals.
You have to seek outpharmaceutical grade suppliers.
Secondly, be prepared for thecosmetic consequences.
MB is a dye and a potent one.
It will turn your tongue, yourteeth, and your urine a bright
(11:21):
blue.
It's a very obvious indicatorthat you've consumed it.
SPEAKER_01 (11:24):
And while consumer interest is booming, we should
know that MB isn't completelyforeign to institutional
medicine.
It is used in certain hospitalsettings, right?
SPEAKER_00 (11:32):
Absolutely.
4V infusions of pharmaceuticalgrade methylene blue are a
medically approved treatment forspecific conditions, like
methmoglobinemia, which is ablood disorder.
The key takeaway there is thatit can be administered safely
and effectively, but only understrict medical supervision where
dosage and interactions can bemeticulously controlled.
SPEAKER_01 (11:52):
So we have a powerful mechanism, historical
use, compelling preliminarydata.
Why then are we not seeing thedefinitive large-scale phase
three clinical trials, therandomized controlled trials
that would solidify MB's placein modern medicine?
SPEAKER_00 (12:07):
The answer, unfortunately, is purely
economic.
Methylene blue has been aroundfor over a century.
It's off-patent.
There is zero intellectualproperty protection.
SPEAKER_01 (12:16):
Aaron Powell Meaning there's no profit incentive.
SPEAKER_00 (12:18):
Precisely.
To develop a drug for alarge-scale indication like
Alzheimer's or schizophrenia, itrequires investing hundreds of
millions, sometimes billions ofdollars, into large-scale safety
and efficacy trials.
No pharmaceutical company isgoing to make that investment if
the resulting drug can't bepatented and protected for
profit.
And this leaves a massive andfrustrating gap.
(12:38):
The compound is promising, theneed is great, but the financial
structure of medical innovationjust leaves it in research
limbo, limited to smalleracademic or government-funded
pilot studies.
SPEAKER_01 (12:48):
So, what does this all mean when we bring these
points together?
We have identified methyleneblue as an incredibly potent,
inexpensive mitochondrial agent.
It has undeniable potential toaddress deep physiological
issues like oxidative stress andmitochondrial decay factors
driving aging and a host ofdisorders.
Yet it sits on the sharp edge ofa razor blade.
(13:10):
It carries a serious,potentially fatal
pharmacological risk serotoninsyndrome.
If the dosage is misjudged or ifit interacts with common
medications, it's a genuinehigh-stakes dichotomy.
SPEAKER_00 (13:21):
It is a perfect encapsulation of the current
landscape of healthinterventions.
And that leaves us with aprovocative question for you to
consider.
Given this powerful mechanismand the consistent, promising
preliminary data, data thatcan't progress because of its
off patent economic status, howshould you, as an individual
seeking to optimize your health,weigh that potential reward
against the serious, welldocumented pharmacological risks
(13:43):
before pursuing such a novelintervention?
The balance between curiosityand caution has never been more
critical.
SPEAKER_01 (13:49):
A compelling and essential thought to Mullover.
Thank you for joining us on thisdeep dive.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.